You are here :
MADIT-CRT

 
MADIT-CRT trial results:
Clinical evidence that early CRT intervention slows the progression of heart failure

The Multicenter Automatic Defibrillator Implantation Trial – Cardiac Resynchronization Therapy (MADIT-CRT) is the largest randomized, NYHA Class I/II CRT-D trial to date, with over 1800 patients enrolled at 110 centers in 14 countries. MADIT-CRT is designed to assess whether early intervention with CRT can slow the progression of heart failure.
Like MADIT and MADIT II, the MADIT-CRT trial is being sponsored by Boston Scientific and conducted under the leadership of principal investigator Dr. Arthur J. Moss, Professor of Medicine at the University of Rochester.

Purpose
Assess wether CRT-D therapy will reduce the risk of mortality and heart failure events in high-risk (QRS≥130ms, EF≤30%) NYHA I-II patients compared to ICD only

Design 1
Primary endpoint1
Combined all-cause mortality or heart failure event, whichever comes first

Results2
Remarkably early response in the CRT-D arm – within the first 2 months

• 34% reduction in all-cause motality or first HF event compared to ICD only (p=0.001)
• Benefit driven by 41% reduction in the risk of HF events (p<0.001)
• Similar benefit for ischemic and non-ischemic patients

Risk of death or heart failure
Legend :
* Hazard ratios are for patients in the CRT-ICD group as compared with those in the ICD-only group.
‡ This category excludes deaths that occurred after the first HF event.
¶ This value is for the primary analysis and takes into account the sequential stopping rule.
† This category includes all deaths, including those that occurred after the first HF event.
§ The difference in hazard ratios between patients with ischemic heart disease and those with non-ischemic heart disease was not significant.

Improvement in hemodynamic function (LV volumes & EF) is seen at just 12 months
Conclusion
MADIT-CRT provides clinical evidence that early CRT intervention in high-risk (QRS≥130ms, EF≤30%), NYHA Class I/II heart failure patients significantly slows the progression of heart failure when compared to ICD only.

References
1 - Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT): design and clinical protocol. Moss A.J. et al. ANE 2005; 10: 43-43
2 - Cardiac resynchronization therapy for the prevention of heart-failure events. Moss A.J. et al. for the MADIT-CRT Trial Investigators. N Engl J Med 2009; 361: 1329-1338

Arthur J. Moss, MD

Discover Arthur J. Moss to learn more about MADIT-CRT hot news Arthur J. Moss, MD, Arthur J. Moss, MD, Principle Investigator of MADIT-CRT clinical trial. Professor of Medicine (Cardiology)/Heart Research Follow-up Program. University of Rochester



Content is under the responsibility of their respective authors and may not reflect the opinion of BSC.

MADIT-CRT design & results (click here to download ppt presentation)

The objective of the MADIT-CRT trial was to demonstrate early CRT intervention slows the progression of heart failure in high-risk (QRS≥130ms, EF≤30%), mildly symptomatic patients (NYHA I/II) compared to ICD only. This file contains information on:

• Study background
• Study Design & protocol
• Patient / Baseline Characteristics
• Study Endpoints
• Study results

MADIT-CRT trial brochure (click here to download the pdf)

This brochure contains information on the MADIT-CRT Trial: Design & protocol, Endpoint, Results, with, in addition a leaflet showing why LATITUDE enabled COGNIS® is the optimal treatment solution for your MADIT-CRT patients

To learn more about MADIT-CRT…